Resources

All the latest from Verge

Read our most recent News, Publications, and Blog posts.

News April 7, 2025

Digital biomarkers detect short-term ALS progression in VRG50635 trial run-in

In the pre-treatment run-in for the VRG50635 ALS proof-of-concept study, multiple at-home digital endpoints — mobility, breathing, sleep, and speech — captured statistically significant changes in just eight weeks, pointing to a more sensitive design for ALS clinical trials.

News November 20, 2024

Lilly selects two ALS targets from CONVERGE® collaboration

News November 29, 2023

VRG50635 proof-of-concept study initiated in patients with ALS

News October 31, 2023

Verge Genomics and the Pritzker Consortium form schizophrenia research collaboration

News September 8, 2023

Verge Genomics and Alexion launch AI-enabled drug discovery collaboration for rare neuro diseases

News June 15, 2023

Positive Phase 1 safety and tolerability data for VRG50635

News November 14, 2022

Alice Zhang named to Fortune 40 Under 40 and Fierce Biotech's Fiercest Women in Life Sciences

News October 31, 2022

First-in-human dosing of VRG50635 begins in Phase 1 trial

News October 12, 2022

Alice Zhang honored by Goldman Sachs as one of 2022's Most Exceptional Entrepreneurs

News September 12, 2022

Fierce Biotech names Verge Genomics a 2022 "Fierce 15" biotech company

News July 8, 2021

Verge Genomics and Eli Lilly announce three-year ALS collaboration

News October 5, 2020

New approach for uncovering novel drug targets from human genetics published in PLOS Computational Biology